RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Envisia Therapeutics today announced that it will present initial findings from its ENV515 program at the Glaucoma 360 New Horizons Forum on Friday, February 7, 2014 at the Palace Hotel in San Francisco. The presentation marks the company’s first data presentation since its foundation last November. The conference, presented by Glaucoma Research Foundation (GRF), provides a forum for unique exchange on research innovation and advances in glaucoma treatment. Globally, glaucoma is a leading cause of preventable blindness.
“We are excited to share for the first time data supporting our lead pipeline product, ENV515, as well as insights into the transformational technology we are using for the development of innovative ocular therapies,” said Ben Yerxa, PhD, Chief Scientific Officer of Envisia.
ENV515 is an implantable, extended-release formulation of a marketed prostaglandin analogue that has the potential to offer glaucoma patients a therapeutic option that can sustain the reduction in intraocular pressure (IOP) over many months. Envisia uses the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats.
Dr. Yerxa will present Precisely Engineered Particles for Ocular Drug Delivery: ENV515 for Glaucoma and Beyond as part of a moderated session titled New Horizons in Glaucoma Drug Delivery, which begins at 9:30 am.
ABOUT GLAUCOMA RESEARCH FOUNDATION
The Glaucoma Research Foundation is America’s oldest and most experienced nonprofit dedicated solely to vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $40 million to advance essential research and education programs.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.